Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSV | O60911 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 2/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22886636 | 1.00 | DCAF1 (0.48) | DCAF1CTSLCTSVCTSSCTSK | |
| SCHEMBL22886629 | 0.91 | DCAF1 (0.50) | DCAF1CTSLCTSVCTSSCTSK | |
| SCHEMBL22886559 | 0.90 | CAPN1 (0.47) | DCAF1CTSLCTSVCTSSCTSK | |
| SCHEMBL22886415 | 0.90 | DCAF1 (0.52) | DCAF1CTSLCTSVCTSSCTSK | |
| SCHEMBL21854327 | 0.90 | DCAF1 (0.53) | DCAF1CTSLCTSVCTSSCTSK | |
| SCHEMBL20027495 | 0.90 | DCAF1 (0.53) | DCAF1CTSLCTSVCTSSCTSK | |
| Hydrochloric Acid SCHEMBL30133652 | 0.89 | DCAF1 (0.52) | DCAF1CTSLCTSVCTSSCTSK | |
| SCHEMBL22885972 | 0.85 | CTSL (0.42) | DCAF1CTSLCTSVCTSSCTSK | |
| SCHEMBL22886627 | 0.83 | PYGL (0.48) | DCAF1CTSLCTSVCTSSCTSK | |
| SCHEMBL20028183 | 0.83 | CAPN1 (0.47) | DCAF1CTSLCTSVCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | BLADE THERAPEUTICS INC (US) | 2022-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | CAPNS1, CAPN9, CAPN2 | DCAF1 3032/4885CTSL 54/4885CTSV 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.